Telbivudine in chronic lymphocytic myocarditis and human parvovirus B19 transcriptional activity

ESC Heart Failure

Volumn 5, Issue 5, 2018, Pages 818-829

  Van Linthout, Sophie ^a   Elsanhoury, Ahmed ^a   Klein, Oliver ^a   Sosnowski, Marzena ^a   Miteva, Kapka ^a   Lassner, Dirk ^b   Abou El Enein, Mohamed ^a   Pieske, Burkert ^a   Kühl, Uwe ^a   Tschöpe, Carsten ^a  

^a BERLIN INSTITUTE OF HEALTH   (Germany)

^b Institut Kardiale Diagnostik und Therapie (IKDT)   (Germany)

Author keywords

Endothelial cells; Myocarditis; Parvovirus B19; Pleiotropic effects; Telbivudine

Indexed keywords

ANGIOTENSIN II; BETA INTERFERON; CD3 ANTIGEN; MESSENGER RNA; PROTEIN VP1; PROTEIN VP2; TELBIVUDINE; TENASCIN; TRANSFORMING GROWTH FACTOR BETA1; TUMOR NECROSIS FACTOR; ANTIVIRUS AGENT; VIRUS DNA;

ADULT; APOPTOSIS; ARTICLE; CELL DAMAGE; CELL PROTECTION; CLINICAL ARTICLE; CONTROLLED STUDY; DOWN REGULATION; DRUG MECHANISM; ENDOTHELIUM CELL; EPITHELIAL MESENCHYMAL TRANSITION; ERYTHEMA INFECTIOSUM; FEMALE; FOLLOW UP; GENE DOSAGE; GENE EXPRESSION REGULATION; HEART EJECTION FRACTION; HEART MUSCLE BIOPSY; HL-1 CELL LINE; HMEC-1 CELL LINE; HUMAN; HUMAN CELL; HUMAN PARVOVIRUS B19; IFN BETA GENE; IN VITRO STUDY; MALE; MATRIX-ASSISTED LASER DESORPTION-IONIZATION MASS SPECTROMETRY; NEW YORK HEART ASSOCIATION CLASS; NONHUMAN; OXIDATIVE STRESS; PLEIOTROPY; PRIORITY JOURNAL; PROTEIN EXPRESSION; TENASCIN C GENE; TGF BETA1 GENE; TRANSCRIPTION INITIATION; UPREGULATION; VIRUS MYOCARDITIS; VIRUS PARTICLE; VP1 GENE; VP2 GENE; CARDIAC MUSCLE; CELL LINE; CHRONIC DISEASE; DIAGNOSTIC IMAGING; DRUG EFFECT; FLOW CYTOMETRY; GENETICS; HEART VENTRICLE; LYMPHOCYTE; METABOLISM; MIDDLE AGED; MYOCARDITIS; PATHOLOGY; VASCULAR ENDOTHELIUM; VIROLOGY;

ANTIVIRAL AGENTS; APOPTOSIS; CELL LINE; CHRONIC DISEASE; DNA, VIRAL; ENDOTHELIUM, VASCULAR; FEMALE; FLOW CYTOMETRY; HEART VENTRICLES; HUMANS; LYMPHOCYTES; MALE; MIDDLE AGED; MYOCARDITIS; MYOCARDIUM; PARVOVIRUS B19, HUMAN; TELBIVUDINE;

EID: 85052399686     PISSN: None     EISSN: 20555822     Source Type: Journal    
DOI: 10.1002/ehf2.12341     Document Type: Article

References (50)

1. Adamson-Small LA, Ignatovich IV, Laemmerhirt MG, Hobbs JA. Persistent parvovirus B19 infection in non-erythroid tissues: possible role in the inflammatory and disease process. Virus Res 2014; 190: 8–16.
2. Bultmann BD, Sotlar K, Klingel K. Parvovirus B19. N Engl J Med 2004; 350: 2006–2007 author reply 2006-7.
3. Bock CT, Klingel K, Kandolf R. Human parvovirus B19-associated myocarditis. N Engl J Med 2010; 362: 1248–1249.
4. Schmidt-Lucke C, Spillmann F, Bock T, Kuhl U, Van Linthout S, Schultheiss HP, Tschope C. Interferon beta modulates endothelial damage in patients with cardiac persistence of human parvovirus B19 infection. J Infect Dis 2010; 201: 936–945.
5. Tschope C, Bock CT, Kasner M, Noutsias M, Westermann D, Schwimmbeck PL, Pauschinger M, Poller WC, Kuhl U, Kandolf R, Schultheiss HP. High prevalence of cardiac parvovirus B19 infection in patients with isolated left ventricular diastolic dysfunction. Circulation 2005; 111: 879–886.
6. Bachelier K, Biehl S, Schwarz V, Kindermann I, Kandolf R, Sauter M, Ukena C, Yilmaz A, Sliwa K, Bock CT, Klingel K, Bohm M. Parvovirus B19-induced vascular damage in the heart is associated with elevated circulating endothelial microparticles. PLoS One 2017; 12: e0176311.
7. Kuhl U, Lassner D, Pauschinger M, Gross UM, Seeberg B, Noutsias M, Poller W, Schultheiss HP. Prevalence of erythrovirus genotypes in the myocardium of patients with dilated cardiomyopathy. J Med Virol 2008; 80: 1243–1251.
8. Schenk T, Enders M, Pollak S, Hahn R, Huzly D. High prevalence of human parvovirus B19 DNA in myocardial autopsy samples from subjects without myocarditis or dilative cardiomyopathy. J Clin Microbiol 2009; 47: 106–110.
9. Lotze U, Egerer R, Gluck B, Zell R, Sigusch H, Erhardt C, Heim A, Kandolf R, Bock T, Wutzler P, Figulla HR. Low level myocardial parvovirus B19 persistence is a frequent finding in patients with heart disease but unrelated to ongoing myocardial injury. J Med Virol 2010; 82: 1449–1457.
10. Koepsell SA, Anderson DR, Radio SJ. Parvovirus B19 is a bystander in adult myocarditis. Cardiovasc Pathol 2012; 21: 476–481.
11. Bihari C, Rastogi A, Saxena P, Rangegowda D, Chowdhury A, Gupta N, Sarin SK. Parvovirus B19 associated hepatitis. Hepat Res Treat 2013; 2013: 472027.
12. Naciute M, Mieliauskaite D, Rugiene R, Maciunaite G, Mauricas M, Murovska M, Girkontaite I. Parvovirus B19 infection modulates the levels of cytokines in the plasma of rheumatoid arthritis patients. Cytokine 2017; 96: 41–48.
13. Gama BE, Emmel VE, Oliveira-Silva M, Gutiyama LM, Arcuri L, Colares M, de Cassia Tavares R, Bouzas LF, Abdelhay E, Hassan R. Parvovirus B19 in the context of hematopoietic stem cell transplantation: evaluating cell donors and recipients. Transplant Direct 2017; 3: e217.
14. Kupin WL. Viral-associated GN: hepatitis B and other viral infections. Clin J Am Soc Nephrol 2017; 12: 1529–1533.
15. Kuhl U, Pauschinger M, Noutsias M, Seeberg B, Bock T, Lassner D, Poller W, Kandolf R, Schultheiss HP. High prevalence of viral genomes and multiple viral infections in the myocardium of adults with “idiopathic” left ventricular dysfunction. Circulation 2005; 111: 887–893.
16. Kuhl U, Lassner D, Dorner A, Rohde M, Escher F, Seeberg B, Hertel E, Tschope C, Skurk C, Gross UM, Schultheiss HP, Poller W. A distinct subgroup of cardiomyopathy patients characterized by transcriptionally active cardiotropic erythrovirus and altered cardiac gene expression. Basic Res Cardiol 2013; 108: 372.
17. Bock CT, Duchting A, Utta F, Brunner E, Sy BT, Klingel K, Lang F, Gawaz M, Felix SB, Kandolf R. Molecular phenotypes of human parvovirus B19 in patients with myocarditis. World J Cardiol 2014; 6: 183–195.
18. Dennert R, van Paassen P, Wolffs P, Bruggeman C, Velthuis S, Felix S, van Suylen RJ, Crijns HJ, Cohen Tervaert JW, Heymans S. Differences in virus prevalence and load in the hearts of patients with idiopathic dilated cardiomyopathy with and without immune-mediated inflammatory diseases. Clin Vaccine Immunol 2012; 19: 1182–1187.
19. Van Linthout S, Tschope C, Schultheiss HP. Lack in treatment options for virus-induced inflammatory cardiomyopathy: can iPS-derived cardiomyocytes close the gap? Circ Res 2014; 115: 540–541.
20. Duechting A, Tschope C, Kaiser H, Lamkemeyer T, Tanaka N, Aberle S, Lang F, Torresi J, Kandolf R, Bock CT. Human parvovirus B19 NS1 protein modulates inflammatory signaling by activation of STAT3/PIAS3 in human endothelial cells. J Virol 2008; 82: 7942–7952.
21. Schmidt-Lucke C, Zobel T, Schrepfer S, Kuhl U, Wang D, Klingel K, Becher PM, Fechner H, Pozzuto T, Van Linthout S, Lassner D, Spillmann F, Escher F, Holinski S, Volk HD, Schultheiss HP, Tschope C. Impaired endothelial regeneration through human parvovirus B19-infected circulating angiogenic cells in patients with cardiomyopathy. J Infect Dis 2015; 212: 1070–1081.
22. Schmidt-Lucke C, Zobel T, Escher F, Tschope C, Lassner D, Kuhl U, Gubbe K, Volk HD, Schultheiss HP. Human parvovirus B19 (B19V) up-regulates CXCR4 surface expression of circulating angiogenic cells: implications for cardiac ischemia in B19V cardiomyopathy. J Infect Dis 2018; 217: 456–465.
23. Dettmeyer R, Kandolf R, Baasner A, Banaschak S, Eis-Hubinger AM, Madea B. Fatal parvovirus B19 myocarditis in an 8-year-old boy. J Forensic Sci 2003; 48: 183–186.
24. Meng N, Gao X, Yan W, Wang M, Liu P, Lu XD, Zhang SJ, Lu YQ, Tang WX. Efficacy of telbivudine in the treatment of chronic hepatitis B and liver cirrhosis and its effect on immunological responses. J Huazhong Univ Sci Technolog Med Sci 2015; 35: 230–234.
25. Pan X, Yao W, Fu J, Liu M, Li L, Gao X. Telbivudine improves the function of myeloid dendritic cells in patients with chronic hepatitis B. Acta Virol 2012; 56: 31–38.
26. Li J, Jia M, Liu Y, She W, Li L, Wang J, Jiang W. Telbivudine therapy may shape CD4(+) T-cell response to prevent liver fibrosis in patients with chronic hepatitis B. Liver Int 2015; 35: 834–845.
27. Chen Y, Li X, Ye B, Yang X, Wu W, Chen B, Pan X, Cao H, Li L. Effect of telbivudine therapy on the cellular immune response in chronic hepatitis B. Antiviral Res 2011; 91: 23–31.
28. Ozawa K, Kurtzman G, Young N. Productive infection by B19 parvovirus of human erythroid bone marrow cells in vitro. Blood 1987; 70: 384–391.
29. Van Linthout S, Savvatis K, Miteva K, Peng J, Ringe J, Warstat K, Schmidt-Lucke C, Sittinger M, Schultheiss HP, Tschope C. Mesenchymal stem cells improve murine acute coxsackievirus B3-induced myocarditis. Eur Heart J 2011; 32: 2168–2178.
30. Spillmann F, Miteva K, Pieske B, Tschope C, Van Linthout S. High-density lipoproteins reduce endothelial-to-mesenchymal transition. Arterioscler Thromb Vasc Biol 2015; 35: 1774–1777.
31. Miteva K, Van Linthout S, Pappritz K, Muller I, Spillmann F, Haag M, Stachelscheid H, Ringe J, Sittinger M, Tschope C. Human endomyocardial biopsy specimen-derived stromal cells modulate angiotensin II-induced cardiac remodeling. Stem Cells Transl Med 2016; 5: 1707–1718.
32. Tschope C, Kherad B, Schultheiss HP. How to perform an endomyocardial biopsy? Turk Kardiyol Dern Ars 2015; 43: 572–575.
33. Dominguez F, Kuhl U, Pieske B, Garcia-Pavia P, Tschöpe C. Update on myocarditis and inflammatory cardiomyopathy: reemergence of endomyocardial biopsy. Rev Esp Cardiol (Engl Ed) 2016; 69: 178–187.
34. Caforio AL, Pankuweit S, Arbustini E, Basso C, Gimeno-Blanes J, Felix SB, Fu M, Helio T, Heymans S, Jahns R, Klingel K, Linhart A, Maisch B, McKenna W, Mogensen J, Pinto YM, Ristic A, Schultheiss HP, Seggewiss H, Tavazzi L, Thiene G, Yilmaz A, Charron P, Elliott PM, M. European Society of Cardiology Working Group on, D. Pericardial. Current state of knowledge on aetiology, diagnosis, management, and therapy of myocarditis: a position statement of the European Society of Cardiology Working Group on Myocardial and Pericardial Diseases. Eur Heart J 2013; 34: 2636–2648, 2648a-2648d.
35. Noutsias M, Seeberg B, Schultheiss HP, Kuhl U. Expression of cell adhesion molecules in dilated cardiomyopathy: evidence for endothelial activation in inflammatory cardiomyopathy. Circulation 1999; 99: 2124–2131.
36. Noutsias M, Pauschinger M, Ostermann K, Escher F, Blohm JH, Schultheiss H, Kuhl U. Digital image analysis system for the quantification of infiltrates and cell adhesion molecules in inflammatory cardiomyopathy. Med Sci Monit 2002; 8: MT59–MT71.
37. Aretz HT. Myocarditis: the Dallas criteria. Hum Pathol 1987; 18: 619–624.
38. Klerk LA, Dankers PY, Popa ER, Bosman AW, Sanders ME, Reedquist KA, Heeren RM. TOF-secondary ion mass spectrometry imaging of polymeric scaffolds with surrounding tissue after in vivo implantation. Anal Chem 2010; 82: 4337–4343.
39. Zeisberg EM, Tarnavski O, Zeisberg M, Dorfman AL, McMullen JR, Gustafsson E, Chandraker A, Yuan X, Pu WT, Roberts AB, Neilson EG, Sayegh MH, Izumo S, Kalluri R. Endothelial-to-mesenchymal transition contributes to cardiac fibrosis. Nat Med 2007; 13: 952–961.
40. Guan W, Wong S, Zhi N, Qiu J. The genome of human parvovirus B19 can replicate in nonpermissive cells with the help of adenovirus genes and produces infectious virus. J Virol 2009; 83: 9541–9553.
41. Rieder F, Kessler SP, West GA, Bhilocha S, de la Motte C, Sadler TM, Gopalan B, Stylianou E, Fiocchi C. Inflammation-induced endothelial-to-mesenchymal transition: a novel mechanism of intestinal fibrosis. Am J Pathol 2011; 179: 2660–2673.
42. Kindermann I, Kindermann M, Kandolf R, Klingel K, Bultmann B, Muller T, Lindinger A, Bohm M. Predictors of outcome in patients with suspected myocarditis. Circulation 2008; 118: 639–648.
43. Frustaci A, Chimenti C, Calabrese F, Pieroni M, Thiene G, Maseri A. Immunosuppressive therapy for active lymphocytic myocarditis: virological and immunologic profile of responders versus nonresponders. Circulation 2003; 107: 857–863.
44. Frustaci A, Russo MA, Chimenti C. Randomized study on the efficacy of immunosuppressive therapy in patients with virus-negative inflammatory cardiomyopathy: the TIMIC study. Eur Heart J 2009; 30: 1995–2002.
45. Escher F, Kuhl U, Lassner D, Poller W, Westermann D, Pieske B, Tschope C, Schultheiss HP. Long-term outcome of patients with virus-negative chronic myocarditis or inflammatory cardiomyopathy after immunosuppressive therapy. Clin Res Cardiol 2016; 105: 1011–1020.
46. Kuhl U, Pauschinger M, Seeberg B, Lassner D, Noutsias M, Poller W, Schultheiss HP. Viral persistence in the myocardium is associated with progressive cardiac dysfunction. Circulation 2005; 112: 1965–1970.
47. Verdonschot J, Hazebroek M, Merken J, Debing Y, Dennert R, Brunner-La Rocca HP, Heymans S. Relevance of cardiac parvovirus B19 in myocarditis and dilated cardiomyopathy: review of the literature. Eur J Heart Fail 2016; 18: 1430–1441.
48. Takahashi Y, Sawada G, Kurashige J, Matsumura T, Uchi R, Ueo H, Ishibashi M, Takano Y, Akiyoshi S, Iwaya T, Eguchi H, Sudo T, Sugimachi K, Yamamoto H, Doki Y, Mori M, Mimori K. Tumor-derived tenascin-C promotes the epithelial-mesenchymal transition in colorectal cancer cells. Anticancer Res 2013; 33: 1927–1934.
49. Brutsaert DL. Cardiac endothelial-myocardial signaling: its role in cardiac growth, contractile performance, and rhythmicity. Physiol Rev 2003; 83: 59–115.
50. Abbadi D, Laroumanie F, Bizou M, Pozzo J, Daviaud D, Delage C, Calise D, Gaits-Iacovoni F, Dutaur M, Tortosa F, Renaud-Gabardos E, Douin-Echinard V, Prats AC, Roncalli J, Parini A, Pizzinat N. Local production of tenascin-C acts as a trigger for monocyte/macrophage recruitment that provokes cardiac dysfunction. Cardiovasc Res 2018; 114: 123–137